FORM 8-K Current Report

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 6, 2011


VolitionRX Limited

 (Exact name of registrant as specified in its charter)

 

 

 

 

Delaware

0-24707

91-1949078

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of Incorporation)

 

Identification Number)

 


150 Orchard Road

Orchard Plaza 08-02

Singapore 238841

 

 

(Address of principal executive offices)

 

 

(201) 618-1750

 

 

(Registrant’s Telephone Number)

 


Copy of all Communications to:

Carrillo Huettel, LLP

3033 Fifth Avenue, Suite 400

San Diego, CA 92103

Telephone: 619.546.6100

Fax: 619.546.6060



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

      . Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 


      . Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 


      . Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


      . Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 





VOLITIONRX LIMITED

Form 8-K

Current Report


ITEM 5.02.

DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS


Effective December 6, 2011, Kevin John Alexander (“Mr. Alexander”) resigned from all positions with the Company including, but not limited to, that of Director.  Mr. Alexander’s resignation did not involve any disagreement with the Company on any matter relating to the Company’s operations, policies, practices, or otherwise.


On December 14, 2011, the Company’s Board of Directors accepted Mr. Alexander’s resignation.


  

SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  

  

  

  

  

VOLITIONRX LIMITED

  

Date: December 19, 2011

By:  

/s/ Cameron Reynolds

 

  

  

Cameron Reynolds

  

  

Chief Executive Officer & President